Public Calendar: August 23-29, 2020
This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.
Official Name: Stephen M. Hahn, M.D., Commissioner of Food and Drugs
No Significant Event
Official Name: Amy Abernethy, M.D., Ph.D, Principal Deputy Commissioner
Event Date: 08/25/2020
Location: Virtual
Subject: Healthcare Information and Management Systems Society (HIMSS) Webinar: Clinical Care and Clinical Research Together
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, academics, patient groups, and other stakeholders
Official Name: Anand Shah, M.D., Deputy Commissioner for Medical and Scientific Affairs
No Significant Event
Official Name: Anna Abram, Deputy Commissioner for Policy, Legislation, and International Affairs
No Significant Event
Official Name: Jim Sigg, Deputy Commissioner for Operations
No Significant Event
Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response
Event Date: 08/26/2020
Location: Virtual
Subject: Food & Beverage Industry Alliance Town Hall
FDA Participant/Group: KARI IRVIN; ANDREAS KELLER; DONALD PRATER; MARK MOORMAN; SHARON MAYL;
Non FDA Participant/Group: Members from the food and beverage industry
Official Name: Lowell Schiller, Principal Associate Commissioner for Policy
No Significant Event
Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy
No Significant Event
Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs
No Significant Event
Official Name: John Wagner, Associate Commissioner for External Affairs
No Significant Event
Official Name: RADM Denise Hinton, Chief Scientist
No Significant Event
Official Name: Patrizia Cavazzoni, M.D., Acting Director, Center for Drug Evaluation and Research
No Significant Event
Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research
Event Date: 08/25/2020
Location: Virtual
Subject: Global Orphan Drug Conference: What’s the Takeaway - How Can Rare Diseases Benefit From the Regulatory Process?
FDA Participant/Group: N/A
Non FDA Participant/Group: Rare disease stakeholders
Event Date: 08/26/2020
Location: Virtual
Subject: HHS Advisory Committee on Blood and Tissue Safety and Availability; Experience of FDA: Blood Products Industry
FDA Participant/Group: NICOLE VERDUN;
Non FDA Participant/Group: Members of the HHS Advisory Committee on Blood and Tissue Safety and Availability, blood products community, and the public
Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health
No Significant Event
Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition
No Significant Event
Official Name: Mitchell R. Zeller, J.D., Director, Center for Tobacco Products
No Significant Event
Official Name: Steven Solomon, Director, Center for Veterinary Medicine
No Significant Event
Official Name: William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research
No Significant Event
Official Name: Stacy Cline Amin, Chief Counsel
No Significant Event